Market capitalization | $1.43b |
P/E (TTM) P/E ratio | negative |
P/B ratio (TTM) P/B ratio | 3.51 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-110.99m |
Cash position | $500.95m |
EPS (TTM) EPS | $-3.66 |
P/E forward | negative |
Short interest | 6.51% |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
10 Analysts have issued a Gemini Therapeutics Inc forecast:
10 Analysts have issued a Gemini Therapeutics Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -111 -111 |
65%
65%
|
Net Profit | -91 -91 |
44%
44%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. It is developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration. The company was founded by Johanna Seddon, Paul Barlow and Andrew Herbert on March 3, 2015 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | John Quisel |
Employees | 74 |
Founded | 2017 |
Website | www.discmedicine.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.